Hemab Therapeutics priced an upsized IPO, raising $301.5 million gross proceeds, after selling 16.75 million shares at $18 per share, the top end of its proposed range. The company targets coagulation disorders including Glanzmann thrombasthenia and von Willebrand disease. Separately, Seaport Therapeutics and Hemab were part of a wave of listings that underscored momentum for biotech capital formation in 2026. Hypervision also secured a separate financing for surgical hyperspectral imaging technology, highlighting continued interest in med-tech-enabled diagnostics and intraoperative analytics. The IPOs land as investors look for clearer catalysts across hematology and clinical-stage differentiation, while funding appetite remains attentive to manufacturing feasibility and commercialization timelines.